Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Saagar N. Patel; Mona L. Camacci; Esther M. Bowie

doi:10.1159/000519275

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Saagar N. Patel, Mona L. Camacci, Esther M. Bowie

Department of Ophthalmology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.

Original language	English (US)
Pages (from-to)	57-63
Number of pages	7
Journal	Case Reports in Ophthalmology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1159/000519275
State	Published - Feb 11 2022

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1159/000519275

Cite this

@article{b4aacbc98b0d4b56805152c93ad852ee,

title = "Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor",

abstract = "We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.",

author = "Patel, {Saagar N.} and Camacci, {Mona L.} and Bowie, {Esther M.}",

note = "Publisher Copyright: {\textcopyright} 2022 Authors.",

year = "2022",

month = feb,

day = "11",

doi = "10.1159/000519275",

language = "English (US)",

volume = "13",

pages = "57--63",

journal = "Case Reports in Ophthalmology",

issn = "1663-2699",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

AU - Patel, Saagar N.

AU - Camacci, Mona L.

AU - Bowie, Esther M.

PY - 2022/2/11

Y1 - 2022/2/11

N2 - We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.

AB - We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.

UR - http://www.scopus.com/inward/record.url?scp=85125928465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125928465&partnerID=8YFLogxK

U2 - 10.1159/000519275

DO - 10.1159/000519275

M3 - Article

C2 - 35350233

AN - SCOPUS:85125928465

SN - 1663-2699

VL - 13

SP - 57

EP - 63

JO - Case Reports in Ophthalmology

JF - Case Reports in Ophthalmology

IS - 1

ER -

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this